Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Aleniglipron

Stage Phase 3Stale

Sponsor Gasherbrum Bio, Inc

Route oral

Class Oral small molecule

Mechanism oral small-molecule GLP-1 receptor agonist

Sources

registry, as of 2026-08-10Stale

https://clinicaltrials.gov/study/NCT07654361

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1). Overall status RECRUITING. Phases PHASE3. Lead sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Enrollment 3600. Conditions Obesity; Overweight; Chronic Weight Management. Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination

ClinicalTrials.gov NCT07654361 protocol and results modules

registry, as of 2026-10-20Stale

https://clinicaltrials.gov/study/NCT07654374

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2). Overall status RECRUITING. Phases PHASE3. Lead sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Enrollment 1100. Conditions Obesity; Overweight; Chronic Weight Management; Type2 Diabetes Mellitus. This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 7

ClinicalTrials.gov NCT07654374 protocol and results modules

registry, as of 2026-08-10Stale

https://clinicaltrials.gov/study/NCT06693843

A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity. Overall status COMPLETED. Phases PHASE2. Lead sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Enrollment 230. Conditions Obesity, Overweight, or Chronic Weight Management. This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at least one weight-related comorbidity. Participants

ClinicalTrials.gov NCT06693843 protocol and results modules

registry, as of 2024-04-25Stale

https://clinicaltrials.gov/study/NCT05762471

Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Enrollment 142. Conditions Overweight or Obesity; Type2 Diabetes Mellitus. This study will evaluate safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects on GSBR-1290 in healthy overweight/obese volunteers (HOV) and Type 2 Diabetes Mellitus on Metformin (T2DM) This study includes 5 planned cohorts. Participants will receiv

ClinicalTrials.gov NCT05762471 protocol and results modules

registry, as of 2026-04-28Stale

https://clinicaltrials.gov/study/NCT06703021

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity. Overall status COMPLETED. Phases PHASE2. Lead sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Enrollment 85. Conditions Obesity; Overweight; Chronic Weight Management. Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet an

ClinicalTrials.gov NCT06703021 protocol and results modules

registry, as of 2026-10-14Stale

https://clinicaltrials.gov/study/NCT07169942

Aleniglipron Phase 2 Body Composition Study. Overall status COMPLETED. Phases PHASE2. Lead sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Enrollment 71. Conditions Obesity, Overweight, or Chronic Weight Management. This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending

ClinicalTrials.gov NCT07169942 protocol and results modules

registry, as of 2026-10-21Stale

https://clinicaltrials.gov/study/NCT07400588

Aleniglipron Phase 2 in Type 2 Diabetes Mellitus. Overall status COMPLETED. Phases PHASE2. Lead sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Enrollment 58. Conditions Obese; Obesity; Obesity Type 2 Diabetes Mellitus; Weight Loss. The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 180 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2).

ClinicalTrials.gov NCT07400588 protocol and results modules

registry, as of 2024-02-15Stale

https://clinicaltrials.gov/study/NCT06139055

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants. Overall status UNKNOWN. Phases PHASE1. Lead sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Enrollment 70. Conditions Healthy Volunteers. The purpose of this study is to compare the safety, tolerability, pharmacokinetic (PK), and comparative bioavailability of repeated administration of GSBR-1290 in healthy overweight/obese participants.

ClinicalTrials.gov NCT06139055 protocol and results modules

publication, as of 2026-08-14Stale

https://pubmed.ncbi.nlm.nih.gov/42249138/

randomized, double-blind, placebo-controlled phase 2b trial. Aleniglipron is an oral, small-molecule glucagon-like peptide-1 receptor agonist (GLP1-RA) in development for obesity treatment. The ACCESS phase 2b placebo-controlled, double-blind study randomized 230 adults (mean BMI 39.5 kg m -2 , 54% female) with o

PMID 42249138

Studies

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Registry NCT07654361

Phase Phase 3

Status Recruiting

Enrollment 3600

Start 2026-07-13

aleniglipron Arm 1

Regimen once daily

Weeks 76

Comparator placebo

Population Obesity; Overweight; Chronic Weight Management

aleniglipron Arm 2

Regimen once daily

Weeks 76

Comparator placebo

Population Obesity; Overweight; Chronic Weight Management

aleniglipron Arm 3

Regimen once daily

Weeks 76

Comparator placebo

Population Obesity; Overweight; Chronic Weight Management

Placebo Arm 4

Regimen once daily

Weeks 76

Population Obesity; Overweight; Chronic Weight Management

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Registry NCT07654374

Phase Phase 3

Status Recruiting

Enrollment 1100

Start 2026-07-17

aleniglipron Arm 1

Regimen once daily

Weeks 76

Comparator placebo

Population Obesity; Overweight; Chronic Weight Management; Type2 Diabetes Mellitus

aleniglipron Arm 2

Regimen once daily

Weeks 76

Comparator placebo

Population Obesity; Overweight; Chronic Weight Management; Type2 Diabetes Mellitus

aleniglipron Arm 3

Regimen once daily

Weeks 76

Comparator placebo

Population Obesity; Overweight; Chronic Weight Management; Type2 Diabetes Mellitus

Placebo Arm 4

Regimen once daily

Weeks 76

Population Obesity; Overweight; Chronic Weight Management; Type2 Diabetes Mellitus

ACCESS

Registry NCT06693843

Phase Phase 2

Status Completed

Enrollment 230

Start 2024-10-28

Primary completion 2025-10-24

Study completion 2026-07-09

Catalyst Primary completion. 2025-10-24. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cohort 1

Population Obesity, Overweight, or Chronic Weight Management

Cohort 2

Population Obesity, Overweight, or Chronic Weight Management

Cohort 3

Population Obesity, Overweight, or Chronic Weight Management

Cohort 1 OLE

Population Obesity, Overweight, or Chronic Weight Management

Cohort 2 OLE

Population Obesity, Overweight, or Chronic Weight Management

Cohort 3 OLE

Population Obesity, Overweight, or Chronic Weight Management

Cohort 4 OLE

Population Obesity, Overweight, or Chronic Weight Management

Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

Registry NCT05762471

Phase Phase 1/2

Status Completed

Enrollment 142

Start 2023-01-09

Primary completion 2024-04-11

Study completion 2024-04-11

Cohort 1

Regimen once daily

Weeks 4

Population Overweight or Obesity; Type2 Diabetes Mellitus

Cohort 2

Regimen once daily

Weeks 4

Population Overweight or Obesity; Type2 Diabetes Mellitus

Cohort 3

Regimen once daily

Weeks 4

Population Overweight or Obesity; Type2 Diabetes Mellitus

Cohort 4

Regimen once daily

Weeks 4

Population Overweight or Obesity; Type2 Diabetes Mellitus

Cohort 5

Regimen once daily

Weeks 4

Population Overweight or Obesity; Type2 Diabetes Mellitus

ACCESS II

Registry NCT06703021

Phase Phase 2

Status Completed

Enrollment 85

Start 2024-12-20

Primary completion 2026-01-12

Study completion 2026-01-12

Catalyst Primary completion. 2026-01-12. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Sentinel

Population Obesity; Overweight; Chronic Weight Management

Cohort 1a

Population Obesity; Overweight; Chronic Weight Management

Cohort 1b

Population Obesity; Overweight; Chronic Weight Management

Cohort 1c

Population Obesity; Overweight; Chronic Weight Management

Aleniglipron Phase 2 Body Composition Study

Registry NCT07169942

Phase Phase 2

Status Completed

Enrollment 71

Start 2025-08-15

Primary completion 2026-09-09

Study completion 2026-09-10

Catalyst Primary completion. 2026-09-09. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cohort 1

Population Obesity, Overweight, or Chronic Weight Management

Cohort 2

Population Obesity, Overweight, or Chronic Weight Management

GSBR-1290

Registry NCT07400588

Phase Phase 2

Status Completed

Enrollment 58

Start 2025-12-01

Primary completion 2026-09-18

Study completion 2026-09-18

Catalyst Primary completion. 2026-09-18. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Arm 1: Participants will receive aleniglipron administered orally

Regimen once daily

Comparator placebo

Population Obese; Obesity; Obesity Type 2 Diabetes Mellitus; Weight Loss

Arm 2: Participants will receive a placebo administered orally

Regimen once daily

Population Obese; Obesity; Obesity Type 2 Diabetes Mellitus; Weight Loss

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

Registry NCT06139055

Phase Phase 1

Enrollment 70

Start 2023-10-02

Part 1 (Sequence 1: Capsule to Tablet): GSBR-1290 Capsule/GSBR-1290 Tablet

Regimen once daily

Weeks 9

Comparator placebo

Population Healthy Volunteers

Part 1(Sequence 2: Tablet to Capsule): GSBR-1290 Tablet/GSBR-1290 Capsule

Regimen once daily

Weeks 9

Comparator placebo

Population Healthy Volunteers

Part 2 (Cohort 1): GSBR-1290/Placebo Tablet

Regimen once daily

Weeks 9

Population Healthy Volunteers

Part 2 (Cohort 2): GSBR-1290/Placebo Tablet

Regimen once daily

Weeks 9

Population Healthy Volunteers

Part 2 (Cohort 3): GSBR-1290/Placebo Tablet and GSBR-1290/Placebo Capsule

Regimen once daily

Weeks 9

Population Healthy Volunteers